South Korea Alzheimers Drug Market Size, Share, Growth, and Industry Analysis, By Drug Class (Cholinesterase Inhibitors Donepezil Rivastigmine Galantamine, NMDA Receptor Antagonists Memantine, Combination Drugs Donepezil + Memantine, Anti-Amyloid Monoclonal AntibodiesLecanemab (Leqembi) Aducanumab (Aduhelm) Donanemab (under review) ), By Disease Stage  (Early Stage / Mild Alzheimer€™s, Moderate Alzheimer€™s, Severe Alzheimer€™s, Prodromal / Mild Cognitive Impairment (MCI) ) and Forecast, 2026-2034

South Korea Alzheimers Drug Market Trends

Disease-Modifying Therapy and Biomarker-Led Treatment Are Reshaping Clinical Practice

South Korea is moving beyond conventional neurotransmitter-based symptom control toward amyloid-targeting treatment. Leqembi received MFDS approval in May 2024 and was launched in November 2024 for adults with MCI due to Alzheimer’s disease or mild Alzheimer’s dementia. South Korea became the fourth country to approve the therapy after the United States, Japan and China. The shift increases requirements for amyloid confirmation, MRI monitoring and specialist neurological assessment.

The addressable clinical population is substantial: approximately 1 in 5 older South Koreans was estimated to have MCI and 1 in 10 dementia, while Alzheimer’s accounts for roughly 70% of dementia cases. Average annual nursing and medical expenditure has been estimated at KRW 21.1 million per dementia patient, increasing to KRW 33.1 million for severe dementia. Commercial production-volume disclosures in millions or billions of Alzheimer’s drug units are not publicly available, making treated-patient access and infusion capacity more relevant indicators than manufactured unit volumes.

South Korea Alzheimers Drug Market Drivers

Rapid Population Aging and Earlier Diagnosis Expand South Korea Alzheimers Drug Market Demand

Approximately 900,000 people were living with dementia in South Korea in 2021, with dementia affecting around 10% of people aged 65+ and MCI affecting about 20%. Alzheimer’s represents approximately 70% of dementia cases, creating a sizable therapeutic population. Annual care and medical expenditure of KRW 21.1 million per dementia patient, rising to KRW 33.1 million for severe disease, reinforces the economic incentive for earlier intervention and treatments capable of delaying functional deterioration.

South Korea Alzheimers Drug Market Restraints

Safety Monitoring and Treatment Infrastructure Constrain South Korea Alzheimers Drug Market Growth

Disease-modifying antibody adoption requires more complex infrastructure than oral symptomatic treatment. Anti-amyloid therapies can require amyloid confirmation, repeated infusion and MRI surveillance for amyloid-related imaging abnormalities. International clinical evidence illustrates the monitoring burden: symptomatic ARIA-E has occurred in approximately 3%–6% of donanemab-treated populations depending on dosing regimen, while total radiographic ARIA has reached 29%–36% in studied groups. Such requirements increase specialist capacity, imaging and patient-selection demands even as South Korea manages a dementia population historically estimated near 900,000.

South Korea Alzheimers Drug Market Opportunities

Early Alzheimer’s and MCI Treatment Creates a Larger Disease-Modifying Therapy Window

The approval of lecanemab specifically for MCI due to Alzheimer’s disease and mild Alzheimer’s dementia establishes a commercial pathway focused on treatment before advanced neurodegeneration. Approximately 20% of older South Koreans have been estimated to experience MCI compared with roughly 10% experiencing dementia, while Alzheimer’s constitutes about 70% of dementia. This shifts commercial opportunity toward screening, biomarker confirmation, neurology services and early-stage treatment ecosystems rather than exclusive dependence on late-stage symptomatic management.

Challenges in South Korea Alzheimers Drug Market

High Care Costs, Diagnostic Complexity and Patient Selection Remain Critical Barriers

Clinical access must balance treatment benefits with safety, affordability and infrastructure. Annual dementia-related nursing and medical costs average approximately KRW 21.1 million, while severe cases reach KRW 33.1 million, a difference of roughly 57%. Meanwhile, anti-amyloid therapy introduces PET or biomarker testing, infusion and MRI requirements. With around 900,000 dementia patients historically reported and Alzheimer’s representing approximately 70%, scaling specialist treatment while maintaining appropriate patient selection constitutes a major operational challenge.

South Korea Alzheimers Drug Market Segmentation

The industry is segmented by drug class, disease stage, mechanism of action, drug type, distribution channel and end user. Among supplied quantitative categories, cholinesterase inhibitors represent approximately 36.4% of 2026 drug-class revenue, while Early Stage/Mild Alzheimer’s accounts for approximately 48.2% of 2026 disease-stage revenue.

By Drug Class

Cholinesterase inhibitors, including donepezil, rivastigmine and galantamine, are the largest category, valued at USD 18.51 million in 2026 and projected to reach USD 30.00 million by 2034, representing approximately 36.4% of the 2026 drug-class total and a 6.22% CAGR.

Combination drugs generate USD 14.54 million in 2026 and NMDA receptor antagonists USD 10.19 million. Anti-amyloid monoclonal antibodies contribute USD 5.10 million, while tau aggregation inhibitors contribute USD 2.55 million. Cholinesterase inhibitors are also the fastest-growing supplied drug class at 6.22% CAGR, compared with 6.15% for NMDA antagonists and anti-amyloid antibodies.

By Disease Stage

Early Stage/Mild Alzheimer’s is the largest disease-stage category at USD 24.49 million in 2026, increasing to USD 38.76 million by 2034 at a 5.91% CAGR. It represents approximately 48.2% of the USD 50.86 million disease-stage total in 2026.

Moderate Alzheimer’s reaches USD 12.83 million in 2026, Severe Alzheimer’s USD 7.73 million, and Prodromal/MCI USD 5.81 million. Severe Alzheimer’s is the fastest-growing supplied stage at 6.26% CAGR, reaching USD 12.56 million by 2034.

By Mechanism of Action

Mechanism segmentation comprises amyloid-beta inhibitors, tau protein modulators, neurotransmitter modifiers, anti-inflammatory agents, mitochondrial stabilizers and synaptic-function enhancers. Amyloid-targeting treatment has gained commercial relevance following lecanemab's Korean approval in 2024.

No mechanism-level revenue or CAGR dataset was supplied. Consequently, numerical market sizing is not assigned to these subsegments; their positioning reflects therapeutic mechanism rather than an unsupported allocation of the USD 50.89 million 2026 total.

By Drug Type

Small molecules include established therapies such as donepezil and memantine, whereas biologics include anti-amyloid monoclonal antibodies such as lecanemab. The supplied anti-amyloid category totals USD 5.10 million in 2026, illustrating the emerging commercial role of biologic disease-modifying therapy.

No independent biologics-versus-small-molecules CAGR is supplied. The closest quantified biologic category, anti-amyloid monoclonal antibodies, records 6.15% CAGR through 2034, while the total drug-class dataset records 6.09% CAGR.

By Distribution Channel

Hospital pharmacies, retail pharmacies and online pharmacies constitute the principal channels. Infusion-based monoclonal antibodies increase hospital and specialist involvement, while established oral medicines remain suitable for conventional pharmacy dispensing. The overall quantified industry expands from USD 50.89 million in 2026 to USD 81.54 million in 2034.

Channel-specific revenue and CAGR figures are not included in the supplied tables. Accordingly, no unsupported channel leader or fastest-growing channel is assigned; the overall forecast CAGR remains 6.09%.

By End User

Hospitals, specialty clinics and neurology centers, homecare settings, and academic and research institutions form the end-user structure. Hospitals and neurology centers have increasing strategic importance as amyloid-targeting therapy requires diagnosis, infusion and imaging oversight. Leqembi's Korean indication specifically covers MCI due to Alzheimer’s disease and mild Alzheimer’s dementia.

End-user revenue and CAGR are not separately provided. The quantified national total is USD 50.89 million in 2026, while the disease-stage dataset indicates that early/mild disease alone accounts for USD 24.49 million, demonstrating the growing clinical relevance of early-intervention infrastructure.

South Korea Alzheimers Drug Market Counties Outlook

South Korea is treated as one national geography because no province-, metropolitan-city- or county-level allocation accompanies the mandatory dataset. Therefore, 100% of the supplied national forecast corresponds to South Korea, with no fabricated Seoul, Busan, Gyeonggi or other subnational shares. National drug-class revenue totals USD 50.89 million in 2026 and USD 81.54 million in 2034.

Domestic production volumes by province are not publicly disclosed at the Alzheimer’s-specific drug level. The sector mix is nevertheless concentrated around established symptomatic drugs and emerging disease-modifying biologics: cholinesterase inhibitors contribute 36.4%, combinations 28.6%, NMDA antagonists 20.0%, anti-amyloid antibodies 10.0%, and tau aggregation inhibitors 5.0% of the supplied 2026 drug-class total.

Top players in South Korea Alzheimers Drug Market

• Eisai Co., Ltd.
• Biogen Inc.
• Pfizer Inc.
• Novartis AG
• Johnson & Johnson
• Eli Lilly and Company
• Roche
• AbbVie Inc.
• Otsuka Pharmaceutical Co., Ltd.
• Daewoong Pharmaceutical Co., Ltd.
• Hanmi Pharmaceutical Co., Ltd.
• Dong-A ST Co., Ltd.
• SK Biopharmaceuticals Co., Ltd.
• Chong Kun Dang Pharmaceutical Corp.

Top Two Companies

• Eisai Co., Ltd

Eisai occupies a strategically important position in South Korea following MFDS approval of Leqembi inMay 2024and commercial launch inNovember 2024. Eisai Korea distributes the therapy locally and provides product information, while Eisai leads global development and regulatory activity. The supplied anti-amyloid antibody segment represents approximately10.0%of 2026 drug-class revenue, equivalent to USD5.10 million, but company-specific revenue share is not publicly disclosed and therefore is not estimated. Leqembi's positioning in MCI and mild Alzheimer’s aligns directly with the early-treatment population that is becoming increasingly important to neurological care.

• Biogen Inc.

Biogen co-commercializes and co-promotes Leqembi globally with Eisai, giving it exposure to one of the most important disease-modifying therapeutic shifts in Alzheimer’s care. South Korea was thefourth countryto approve Leqembi, while the targeted early-AD population includes patients with MCI and mild dementia. Biogen's exact South Korean revenue percentage is not disclosed; consequently, no unsupported company share is assigned. Its competitive positioning derives from participation in the anti-amyloid class, which represents approximately10.0%of the supplied 2026 drug-class value and is forecast at6.15% CAGRthrough 2034.

Recent Developments in South Korea Alzheimers Drug Market

• 2025:Alzheimer’s therapeutic research continued moving toward multi-target and biomarker-guided approaches, with published modeling research indicating that tau reduction alone may provide limited cognitive benefit and supporting investigation of combined pathological targets.

Research Methodology

The analysis uses 2025 as the base year, 2026 as the current year, historical assessment for 2022–2024, and a forecast horizon extending through 2034. Mandatory supplied values are retained as the primary quantitative source: USD 47.97 million in 2025, USD 50.89 million in 2026 and USD 81.54 million in 2034 for the drug-class dataset, with a 6.09% CAGR. Segment percentages were calculated directly from supplied totals. Public regulatory and company disclosures were used only for contextual validation of approvals, launches, patient prevalence, clinical positioning and competitive developments. No missing provincial, channel, end-user, mechanism or company-level revenue shares were fabricated.